UC-514321|cas:299420-83-0|西域试剂

UC-514321,98.0%

产品编号：Bellancom-120395| CAS NO：299420-83-0| 分子式：C₂₆H₃₅NO₅| 分子量：441.56

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-120395	￥2550.00	杭州北京（现货）
Bellancom-120395	￥4550.00	杭州北京（现货）
Bellancom-120395	￥13950.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

UC-514321

产品介绍

UC-514321 是 NSC370284 的结构类似物，且活性更高，靶向 STAT3/5 并选择性抑制 TET1 的表达。UC-514321 体内体外均表现出良好的抗急性髓系白血病的活性，并具有较低的毒性。

生物活性

UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.

体外研究

UC-514321 increases apoptosis in AML cells not in normal HSPCs.
UC-514321 (0-500 nM, 48 h) inhibits AML cells viability TET1-signaling dependently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	MONOMAC-6, THP-1, KOCL-48, KASUMI-1, ML-2, and NB4 cells.
Concentration:	0-500 nM.
Incubation Time:	48 hours.
Result:	Most significantly repressed MONOMAC-6 cell viability. Showed no inhibitory effect on the viability of TET1-low AML.

RT-PCR

Cell Line:	MONOMAC-6 cells.
Concentration:	0-500 nM.
Incubation Time:	48 hours.
Result:	Functioned as TET1-transcription inhibitors in TET1-high AMLs and their anti-leukemic effects are TET1-dependent.

体内研究
(In Vivo)

UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MLL-AF9-AML mice and AE9a-AML model.
Dosage:	2.5 mg/kg.
Administration:	IP., once per day, for 10 days.
Result:	Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold.

体内研究

UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MLL-AF9-AML mice and AE9a-AML model.
Dosage:	2.5 mg/kg.
Administration:	IP., once per day, for 10 days.
Result:	Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold.

体内研究

UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MLL-AF9-AML mice and AE9a-AML model.
Dosage:	2.5 mg/kg.
Administration:	IP., once per day, for 10 days.
Result:	Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold.

性状

Solid

溶解性数据

In Vitro:

Ethanol : 50 mg/mL (113.23 mM; Need ultrasonic)

DMSO : 25 mg/mL (56.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2647 mL	11.3235 mL	22.6470 mL
5 mM	0.4529 mL	2.2647 mL	4.5294 mL
10 mM	0.2265 mL	1.1323 mL	2.2647 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.66 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.66 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。